Takeda Oncology Products Overview

Takeda Oncology Products Summary

  • ALUNBRIG® (brigatinib)

    • Indication: ALK-positive metastatic non-small cell lung cancer (NSCLC)
    • Patent Expiry: November 2035
    • Status: ~10 years of patent protection remaining

  • FRUZAQLA® (fruquintinib)

    • Indication: Metastatic colorectal cancer (mCRC) - third-line or later
    • Patent Expiry: Early-to-mid 2030s (estimated)
    • Status: Recently launched (November 2023)

  • ICLUSIG® (ponatinib)

    • Indications:
    • Chronic myeloid leukemia (CML) resistant/intolerant to therapy
    • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
    • T315I-positive CML or Ph+ ALL
    • Patent Expiry: January 2027 (primary patents)
    • Extended Exclusivity: March 2031 (for newly diagnosed Ph+ ALL)
    • Status: ~1 year until primary patent expiry

  • NINLARO® (ixazomib)

    • Indication: Multiple myeloma - at least one prior therapy
    • Patent Expiry: November 2029
    • Status: ~4 years of patent protection remaining

  • VELCADE® (bortezomib)

    • Indications:
    • Multiple myeloma
    • Mantle cell lymphoma
    • Patent Expiry: 2017-2022 (already expired)
    • Status: GENERIC AVAILABLE

Patent Cliff Timeline

  • 2017-2022: VELCADE - Patents expired, generics dominate
  • 2027: ICLUSIG - Primary patent expiry (some indications)
  • 2029: NINLARO - Patent expiry, major revenue impact expected
  • 2031: ICLUSIG - Extended exclusivity expires (Ph+ ALL)
  • ~2030s: FRUZAQLA - Estimated patent expiry
  • 2035: ALUNBRIG - Patent expiry, most secure product

Quick Facts

  • Most Patent-Secure Product: ALUNBRIG (until 2035)
  • Nearest Patent Cliff: ICLUSIG (2027)
  • Already Generic: VELCADE (experiencing 80% sales decline)
  • Newest Product: FRUZAQLA (launched November 2023)
  • Largest Revenue Product: NINLARO (~$585M in FY2024, facing patent expiry in 2029)